OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual Meeting
Permanent Abstract Number: 1636
Title: Optimized antagonist anti-PD-1/IL-7 mutein bispecific antibody to sustain exhausted T cell function and to disarm Treg suppressive activity.
Morello A., Seité M., Durand J, Thépenier V., Teppaz G., Pengam S., Wilhelm E., Desselle A., Girault I., Mary C., Poirier N.
Session Type: E-Poster Session
Session Title: Therapeutic Antibodies
Title: Triggering the resolution of inflammation with agonistic anti-ChemR23 antibody dampens inflammation-driven carcinogenesis
Gauttier V., Lavy M., Trilleaud C., Biteau K., Girault I., Belarif L., Teppaz G., Mary C., Thepenier V., Blanquart C., Barillé-Nion S., Poirier N.
Feb 24, 2021
Drug reduced agitation-related events but increased time on vent and length of ICU stay
Critically ill patients on mechanical ventilation who were at risk for alcohol withdrawal syndrome (AWS) had fewer agitation-related events with high-dose baclofen than placebo, a prophylactic treatment trial showed.
However, the effect size was modest and the baclofen group had longer median length of mechanical ventilation (9 versus 8 days) and longer ICU stay (14 versus 11 days) compared with the placebo group, reported Karim Asehnoune, MD, PhD, of D, CHU deNantes in France, and co-authors in
.
“The deeper sedation experienced by patients randomized to receive baclofen compared with placebo may explain both the statistically significant decrease in the primary outcome of at least one agitation-related event and the significant increase in the prespecified secondary end points of duration of mechanical ventilation and of ICU stay,” Asehnoune and colleagues wrote.
Press release content from Business Wire. The AP news staff was not involved in its creation.
VALBIOTIS Authorized to Launch HEART, the Phase II Multi-center Clinical Study With TOTUM-070, for the Reduction of Blood LDL-cholesterol Levels
February 15, 2021 GMT
LA ROCHELLE, France (BUSINESS WIRE) Feb 15, 2021
VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME, French equity savings plan for the financing of SMEs) (Paris:ALVAL), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that it has received a positive opinion from the CPP and authorization from the ANSM to launch HEART, a multi-centric Phase II clinical study with TOTUM-070, for the reduction of blood LDL-cholesterol levels, a risk factor for cardiovascular disease.
Thresholds of glycemia, insulin therapy, and risk for severe retinopathy in premature infants: A cohort study
Affiliation Department of Ophthalmology, Nantes University Hospital, Nantes, France ⨯
Frank Plaisant, Roles Data curation, Investigation, Validation, Writing – review & editing
Affiliation Department of Neonatal Medicine, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France ⨯
Laetitia Marchand-Martin, Roles Formal analysis, Investigation, Methodology, Validation, Writing – review & editing
Affiliation Obstetrical, Perinatal, and Pediatric Epidemiology Team, Centre of Research in Epidemiology and Statistics, INSERM (UMR1153), Paris, France ⨯
Cyril Flamant, Roles Formal analysis, Investigation, Validation, Writing – review & editing
Affiliations Department of Neonatal Medicine, Nantes University Hospital, Nantes, France,